annb0t
Top 20
Neuren Pharmaceuticals Limited (ASX:NEU) came out with its interim results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. It looks like a pretty bad result, all things considered. Although revenues of AU$24m were in line with analyst predictions, statutory earnings fell badly short, missing estimates by 80% to hit AU$0.061 per share. The analysts typically update their forecasts at each earnings report, and...
>>> Read more: Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
>>> Read more: Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
